[Extrahepatic cholestasia during therapy with Zolmitriptan (AscoTop)].
Because of recurrent abdominal pain, jaundice and elevated liver function tests, a sixty-two-year old man had been referred to hospital several times within the preceding six months. By means of ultrasonography, endoscopic retrograde cholangiopancreatography (ERCP) and magnetic resonant cholangiopancreatography, dilated extrahepatic bile ducts were diagnosed. Stones and a tumorous process were excluded. ERCP showed hypermotility of the upper gastrointestinal tract. Quantitative hepatobiliary scintigraphy demonstrated retention of activity in the intra- and extrahepatic bile ducts and delayed transit of activity to the duodenum as signs of papillary dysfunction. Drug anamnesis revealed that the patient had started migraine treatment with Zolmitiptan, a 5-HT (1B/1D)-receptor agonist of the second generation, six months before the beginning of the cholestasia syndrome. Because of the known increase in amplitudes of oesophageal motor waves and of lower oesophageal sphincter tone by Sumatriptan, a 5-HT (1B/1D)-receptor agonist of the first generation, Zolmitriptan treatment was stopped. Thereupon, laboratory findings normalised and the patient has been feeling well for more than one year. Serotonin is an important monamine neurotransmitter that acts both in the CNS and in the gastrointestinal tract on identical receptors and is transported by the same systems. Thus it is not surprising that therapeutic measures which influence the serotoninergic system in the CNS are also effective in the enteric nervous.
Deixler
E
E
IV. Medizinische Abteilung, Rheumatologie und Klinische Immunologie, Städtisches Klinikum München GmbH, Krankenhaus München-Bogenhausen, Akademisches Lehrkrankenhaus der Technischen Universität München.
Helmke
K
K
D017734:Bile Ducts, Extrahepatic / Q000000981:diagnostic imaging*; D001651:Cholestasis, Extrahepatic / Q000139:chemically induced* / Q000175:diagnosis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy; D023303:Oxazolidinones / Q000009:adverse effects* / Q000627:therapeutic use; D011877:Radionuclide Imaging; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use; D014363:Tryptamines
D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan